New Education Materials from NCCN Empower Patients with Rare Lymphoma
New NCCN Guidelines for Patients® and NCCN Quick Guide™ outline disease basics, testing, and treatment information about Mycosis Fungoides so patients can make well-informed decisions about their cancer care.
FORT WASHINGTON, PA —Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. To provide insight for patients with Mycosis Fungoides and ensure they have access to information about their disease, the National Comprehensive Cancer Network® ( NCCN ® ) has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Mycosis Fungoides , completing the series of NCCN Guidelines for Patients®: Non-Hodgkin’s Lymphomas (NHL) . These resources are made possible through funding from the NCCN Foundation ® .
“As part of a relatively small patient population, people diagnosed with Mycosis Fungoides have limited credible resources from which to learn about their disease,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “NCCN Foundation is proud to offer these patients and their caregivers educational resources tailored specifically to their needs in order to empower them to make informed decisions about their health care.”
NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ), are easy-to-understand resources based on the same clinical practice guidelines used by health care professionals around the world to determine the best way to treat a patient with cancer. Each resource features unbiased expert guidance from the nation’s leading cancer centers designed to help people living with cancer talk with their physicians about the best treatment options for their disease. These resources are available free-of-charge at NCCN.org/patientguidelines . Print versions are available to order on Amazon.com.
NCCN Guidelines for Patients and NCCN Quick Guide™ sheets—one-page summaries of key points in the patient guidelines—are written in plain language and include patient-friendly elements, such as questions to ask your doctor, a glossary of terms, and medical illustrations of anatomy, tests, and treatments. NCCN Guidelines for Patients and NCCN Quick Guide™ sheets DO NOT replace the expertise and clinical judgment of the clinician.
NCCN currently offers NCCN Guidelines for Patients for the following: Breast, Colon, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphocytic Leukemia (ALL); Caring for Adolescents and Young Adults; Chronic Lymphocytic Leukemia (CLL); Chronic Myelogenous Leukemia (CML); Hodgkin Lymphoma; Lung Cancer Screening,; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; NHL; and Soft Tissue Sarcoma.
To download the NCCN Guidelines for Patients and NCCN Quick Guide™ for Mycosis Fungoides, visit NCCN.org/patientguidelines .
About NCCN Foundation
Through philanthropy, the NCCN Foundation® empowers people through knowledge and advances the mission of NCCN to improve the quality, effectiveness, and efficiency of cancer care, so that patients can live better lives. Visit NCCNFoundation.org .
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Katie Kiley Brown, NCCN